Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart attack procedure under review: does PCI save more lives?

NCT ID NCT07405788

Disease control Sponsor: Kaiyang Lin Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks over 1,300 heart attack patients who received a procedure called percutaneous coronary intervention (PCI), which opens blocked heart arteries. Researchers want to see if PCI reduces major heart problems like death, another heart attack, or the need for more procedures, compared to standard care. The study also checks for risks like bleeding or kidney issues. It is an observational registry, not a test of a new drug or cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1,344 people

The number who actually took part.

Started

Jan 2017

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

1. Inclusion Criteria: 1. Clinical diagnosis of acute myocardial infarction. 2. Successful direct or emergency PCI of the infarct-related artery. 3. Ability to undergo randomization post-PCI. 4. Ability to understand and voluntarily sign the informed consent form. 2. Exclusion Criteria: 1. PCI failure (final TIMI flow \< grade 2) or presence of untreated severe stenosis. 2. Planned staged PCI or other cardiac surgery within 3 months. 3. Cardiogenic shock (Killip class IV), severe structural heart disease, or contraindications to PCI trial intervention. 4. Active bleeding or high bleeding risk. 5. Known allergy to the trial drug or its components. 6. ALT/AST \> 3x upper limit of normal (ULN); eGFR \< 30 mL/min/1.73 m². 7. Non-cardiovascular disease with life expectancy \< 1 year (e.g., active malignancy). 8. History of hemorrhagic stroke, or any ischemic stroke/transient ischemic attack within the past 6 months. 9. Requirement for long-term oral anticoagulation therapy. 10. Pregnancy, lactation, or women of childbearing potential not using effective contraception. 11. Current participation in another interventional clinical trial. 12. Any condition that may affect trial compliance, safety assessment, or result interpretation per investigator judgment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute myocardial infarction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myocardial infarction myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction

More trials for these conditions

Other studies related to the condition(s) this trial covers.